MASI
Masimo Corp

1,779
Mkt Cap
$9.47B
Volume
764,735.00
52W High
$194.88
52W Low
$125.94
PE Ratio
-12.71
MASI Fundamentals
Price
$134.10
Prev Close
$134.80
Open
$134.76
50D MA
$137.64
Beta
0.97
Avg. Volume
785,577.10
EPS (Annual)
-$5.72
P/B
8.84
Rev/Employee
$227,652.17
$9,778.50
Loading...
Loading...
News
all
press releases
Baxter to Post Q4 Earnings: What's in Store for the Stock?
BAX's fourth-quarter results are likely to reflect muted revenue growth and an EPS decline due to ongoing infusion therapy and IV fluid headwinds.
Zacks·12h ago
News Placeholder
More News
News Placeholder
Will DXCM Deliver Q4 Earnings Beat on G7 Stabilization, Volume Growth?
DexCom heads into Q4 earnings with easing G7 issues, improving supply chains and rebounding U.S. new customer starts lifting revenue outlook.
Zacks·14h ago
News Placeholder
PLSE Shares Positive First-in-Human nPulse Cardiac Catheter Data
Pulse Biosciences shares late-breaking AF data showing up to 100% procedural success, fast procedures and low adverse events for nPulse.
Zacks·2d ago
News Placeholder
WST Q4 Earnings Preview: Can HVP Momentum Continue to Drive Margins?
West Pharmaceutical heads into Q4 with HVP demand likely lifting margins, but tariff risk looms as revenue and EPS targets come into focus.
Zacks·2d ago
News Placeholder
Can Sustained Product Demand Drive BDX Stock Before Q1 Earnings?
BD rides on sustained product demand across Medical, Life Sciences and Interventional, but China market dynamics may pressure first-quarter fiscal 2026 results.
Zacks·6d ago
News Placeholder
Masimo Corporation (NASDAQ:MASI) Given Average Rating of "Hold" by Analysts
Shares of Masimo Corporation (NASDAQ:MASI - Get Free Report) have been assigned a consensus rating of "Hold" from the eight ratings firms that are currently covering the firm, MarketBeat Ratings...
MarketBeat·6d ago
News Placeholder
Pharma, Specialty Units Likely to Drive Cardinal Health's Q2 Earnings
Cardinal Health's second-quarter earnings might have been driven by Pharma and Specialty Solutions, as strong utilization and GLP-1 momentum must have raised revenues and EPS.
Zacks·6d ago
News Placeholder
Here's Why You Should Add Masimo Stock to Your Portfolio Now
MASI targets 7%-10% revenue growth through 2028, sharp margin expansion and rising cash flow as intelligent monitoring and partnerships gain traction.
Zacks·7d ago
News Placeholder
Why Masimo (MASI) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·7d ago
News Placeholder
GE HealthCare Stock Before Q4 Earnings: To Buy or Not to Buy?
GEHC heads into fourth-quarter earnings with steady demand and strong product momentum, though tariffs and investments may keep margins in focus.
Zacks·8d ago
<
1
2
...
>

Latest MASI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.